The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Cancer Immunotherapy Drugs Market Research Report 2024
Synopsis
Immunotherapy is a type of medical treatment that harnesses the body's own immune system to fight diseases, particularly cancer. Unlike traditional treatments such as chemotherapy and radiation therapy, which directly target cancer cells, immunotherapy stimulates the body's natural defenses to identify and destroy cancer cells more effectively. It is a type of personalized treatment. (Immunotherapy is often tailored to the patient's specific cancer and immune system. Biomarker testing is sometimes performed to determine the suitability of certain immunotherapy drugs.)
The global Cancer Immunotherapy Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Cancer Immunotherapy Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cancer Immunotherapy Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Cancer Immunotherapy Drugs in Lung Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Cancer Immunotherapy Drugs include AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Cancer Immunotherapy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Immunotherapy Drugs.
The Cancer Immunotherapy Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Immunotherapy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Immunotherapy Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine
Segment by Type
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
CAR-T Cell Therapy
Other
Segment by Application
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Immunotherapy Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Immunotherapy is a type of medical treatment that harnesses the body's own immune system to fight diseases, particularly cancer. Unlike traditional treatments such as chemotherapy and radiation therapy, which directly target cancer cells, immunotherapy stimulates the body's natural defenses to identify and destroy cancer cells more effectively. It is a type of personalized treatment. (Immunotherapy is often tailored to the patient's specific cancer and immune system. Biomarker testing is sometimes performed to determine the suitability of certain immunotherapy drugs.)
The global Cancer Immunotherapy Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Cancer Immunotherapy Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cancer Immunotherapy Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Cancer Immunotherapy Drugs in Lung Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Cancer Immunotherapy Drugs include AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Cancer Immunotherapy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Immunotherapy Drugs.
The Cancer Immunotherapy Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Immunotherapy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Immunotherapy Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine
Segment by Type
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
CAR-T Cell Therapy
Other
Segment by Application
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Immunotherapy Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Immunotherapy Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Cytokine-Based Immunotherapy
1.2.4 CAR-T Cell Therapy
1.2.5 Other
1.3 Market by Application
1.3.1 Global Cancer Immunotherapy Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Prostate Cancer
1.3.5 Blood-related Cancer
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer Immunotherapy Drugs Market Perspective (2019-2030)
2.2 Global Cancer Immunotherapy Drugs Growth Trends by Region
2.2.1 Global Cancer Immunotherapy Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Cancer Immunotherapy Drugs Historic Market Size by Region (2019-2024)
2.2.3 Cancer Immunotherapy Drugs Forecasted Market Size by Region (2025-2030)
2.3 Cancer Immunotherapy Drugs Market Dynamics
2.3.1 Cancer Immunotherapy Drugs Industry Trends
2.3.2 Cancer Immunotherapy Drugs Market Drivers
2.3.3 Cancer Immunotherapy Drugs Market Challenges
2.3.4 Cancer Immunotherapy Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Immunotherapy Drugs Players by Revenue
3.1.1 Global Top Cancer Immunotherapy Drugs Players by Revenue (2019-2024)
3.1.2 Global Cancer Immunotherapy Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Cancer Immunotherapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Cancer Immunotherapy Drugs Revenue
3.4 Global Cancer Immunotherapy Drugs Market Concentration Ratio
3.4.1 Global Cancer Immunotherapy Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Immunotherapy Drugs Revenue in 2023
3.5 Global Key Players of Cancer Immunotherapy Drugs Head office and Area Served
3.6 Global Key Players of Cancer Immunotherapy Drugs, Product and Application
3.7 Global Key Players of Cancer Immunotherapy Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Immunotherapy Drugs Breakdown Data by Type
4.1 Global Cancer Immunotherapy Drugs Historic Market Size by Type (2019-2024)
4.2 Global Cancer Immunotherapy Drugs Forecasted Market Size by Type (2025-2030)
5 Cancer Immunotherapy Drugs Breakdown Data by Application
5.1 Global Cancer Immunotherapy Drugs Historic Market Size by Application (2019-2024)
5.2 Global Cancer Immunotherapy Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Cancer Immunotherapy Drugs Market Size (2019-2030)
6.2 North America Cancer Immunotherapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Cancer Immunotherapy Drugs Market Size by Country (2019-2024)
6.4 North America Cancer Immunotherapy Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cancer Immunotherapy Drugs Market Size (2019-2030)
7.2 Europe Cancer Immunotherapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Cancer Immunotherapy Drugs Market Size by Country (2019-2024)
7.4 Europe Cancer Immunotherapy Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Immunotherapy Drugs Market Size (2019-2030)
8.2 Asia-Pacific Cancer Immunotherapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Cancer Immunotherapy Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Cancer Immunotherapy Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cancer Immunotherapy Drugs Market Size (2019-2030)
9.2 Latin America Cancer Immunotherapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Cancer Immunotherapy Drugs Market Size by Country (2019-2024)
9.4 Latin America Cancer Immunotherapy Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Immunotherapy Drugs Market Size (2019-2030)
10.2 Middle East & Africa Cancer Immunotherapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Cancer Immunotherapy Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Cancer Immunotherapy Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Cancer Immunotherapy Drugs Introduction
11.1.4 AbbVie Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.1.5 AbbVie Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Cancer Immunotherapy Drugs Introduction
11.2.4 Johnson & Johnson Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.2.5 Johnson & Johnson Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Cancer Immunotherapy Drugs Introduction
11.3.4 Novartis Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Gilead Sciences
11.4.1 Gilead Sciences Company Details
11.4.2 Gilead Sciences Business Overview
11.4.3 Gilead Sciences Cancer Immunotherapy Drugs Introduction
11.4.4 Gilead Sciences Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.4.5 Gilead Sciences Recent Development
11.5 Roche
11.5.1 Roche Company Details
11.5.2 Roche Business Overview
11.5.3 Roche Cancer Immunotherapy Drugs Introduction
11.5.4 Roche Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.5.5 Roche Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Details
11.6.2 Bristol-Myers Squibb Business Overview
11.6.3 Bristol-Myers Squibb Cancer Immunotherapy Drugs Introduction
11.6.4 Bristol-Myers Squibb Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Amgen
11.7.1 Amgen Company Details
11.7.2 Amgen Business Overview
11.7.3 Amgen Cancer Immunotherapy Drugs Introduction
11.7.4 Amgen Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.7.5 Amgen Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Cancer Immunotherapy Drugs Introduction
11.8.4 AstraZeneca Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.8.5 AstraZeneca Recent Development
11.9 Merck & Co
11.9.1 Merck & Co Company Details
11.9.2 Merck & Co Business Overview
11.9.3 Merck & Co Cancer Immunotherapy Drugs Introduction
11.9.4 Merck & Co Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.9.5 Merck & Co Recent Development
11.10 Takeda
11.10.1 Takeda Company Details
11.10.2 Takeda Business Overview
11.10.3 Takeda Cancer Immunotherapy Drugs Introduction
11.10.4 Takeda Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.10.5 Takeda Recent Development
11.11 Merck KGaA
11.11.1 Merck KGaA Company Details
11.11.2 Merck KGaA Business Overview
11.11.3 Merck KGaA Cancer Immunotherapy Drugs Introduction
11.11.4 Merck KGaA Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.11.5 Merck KGaA Recent Development
11.12 Seagen
11.12.1 Seagen Company Details
11.12.2 Seagen Business Overview
11.12.3 Seagen Cancer Immunotherapy Drugs Introduction
11.12.4 Seagen Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.12.5 Seagen Recent Development
11.13 Eli Lilly
11.13.1 Eli Lilly Company Details
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Cancer Immunotherapy Drugs Introduction
11.13.4 Eli Lilly Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.13.5 Eli Lilly Recent Development
11.14 Ono Pharmaceutical
11.14.1 Ono Pharmaceutical Company Details
11.14.2 Ono Pharmaceutical Business Overview
11.14.3 Ono Pharmaceutical Cancer Immunotherapy Drugs Introduction
11.14.4 Ono Pharmaceutical Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.14.5 Ono Pharmaceutical Recent Development
11.15 Pfizer
11.15.1 Pfizer Company Details
11.15.2 Pfizer Business Overview
11.15.3 Pfizer Cancer Immunotherapy Drugs Introduction
11.15.4 Pfizer Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.15.5 Pfizer Recent Development
11.16 GSK
11.16.1 GSK Company Details
11.16.2 GSK Business Overview
11.16.3 GSK Cancer Immunotherapy Drugs Introduction
11.16.4 GSK Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.16.5 GSK Recent Development
11.17 Exelixis
11.17.1 Exelixis Company Details
11.17.2 Exelixis Business Overview
11.17.3 Exelixis Cancer Immunotherapy Drugs Introduction
11.17.4 Exelixis Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.17.5 Exelixis Recent Development
11.18 Regeneron
11.18.1 Regeneron Company Details
11.18.2 Regeneron Business Overview
11.18.3 Regeneron Cancer Immunotherapy Drugs Introduction
11.18.4 Regeneron Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.18.5 Regeneron Recent Development
11.19 Innovent
11.19.1 Innovent Company Details
11.19.2 Innovent Business Overview
11.19.3 Innovent Cancer Immunotherapy Drugs Introduction
11.19.4 Innovent Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.19.5 Innovent Recent Development
11.20 Hengrui Medicine
11.20.1 Hengrui Medicine Company Details
11.20.2 Hengrui Medicine Business Overview
11.20.3 Hengrui Medicine Cancer Immunotherapy Drugs Introduction
11.20.4 Hengrui Medicine Revenue in Cancer Immunotherapy Drugs Business (2019-2024)
11.20.5 Hengrui Medicine Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of TablesList of Tables
Table 1. Global Cancer Immunotherapy Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Immune Checkpoint Inhibitors
Table 3. Key Players of Cytokine-Based Immunotherapy
Table 4. Key Players of CAR-T Cell Therapy
Table 5. Key Players of Other
Table 6. Global Cancer Immunotherapy Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Cancer Immunotherapy Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Cancer Immunotherapy Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Cancer Immunotherapy Drugs Market Share by Region (2019-2024)
Table 10. Global Cancer Immunotherapy Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Cancer Immunotherapy Drugs Market Share by Region (2025-2030)
Table 12. Cancer Immunotherapy Drugs Market Trends
Table 13. Cancer Immunotherapy Drugs Market Drivers
Table 14. Cancer Immunotherapy Drugs Market Challenges
Table 15. Cancer Immunotherapy Drugs Market Restraints
Table 16. Global Cancer Immunotherapy Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Cancer Immunotherapy Drugs Market Share by Players (2019-2024)
Table 18. Global Top Cancer Immunotherapy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Immunotherapy Drugs as of 2023)
Table 19. Ranking of Global Top Cancer Immunotherapy Drugs Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Cancer Immunotherapy Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 21. Global Key Players of Cancer Immunotherapy Drugs, Headquarters and Area Served
Table 22. Global Key Players of Cancer Immunotherapy Drugs, Product and Application
Table 23. Global Key Players of Cancer Immunotherapy Drugs, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Cancer Immunotherapy Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2019-2024)
Table 27. Global Cancer Immunotherapy Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2025-2030)
Table 29. Global Cancer Immunotherapy Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2019-2024)
Table 31. Global Cancer Immunotherapy Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2025-2030)
Table 33. North America Cancer Immunotherapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Cancer Immunotherapy Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Cancer Immunotherapy Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Cancer Immunotherapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Cancer Immunotherapy Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Cancer Immunotherapy Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Cancer Immunotherapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Cancer Immunotherapy Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Cancer Immunotherapy Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Cancer Immunotherapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Cancer Immunotherapy Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Cancer Immunotherapy Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Cancer Immunotherapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Cancer Immunotherapy Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Cancer Immunotherapy Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 48. AbbVie Company Details
Table 49. AbbVie Business Overview
Table 50. AbbVie Cancer Immunotherapy Drugs Product
Table 51. AbbVie Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 52. AbbVie Recent Development
Table 53. Johnson & Johnson Company Details
Table 54. Johnson & Johnson Business Overview
Table 55. Johnson & Johnson Cancer Immunotherapy Drugs Product
Table 56. Johnson & Johnson Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 57. Johnson & Johnson Recent Development
Table 58. Novartis Company Details
Table 59. Novartis Business Overview
Table 60. Novartis Cancer Immunotherapy Drugs Product
Table 61. Novartis Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 62. Novartis Recent Development
Table 63. Gilead Sciences Company Details
Table 64. Gilead Sciences Business Overview
Table 65. Gilead Sciences Cancer Immunotherapy Drugs Product
Table 66. Gilead Sciences Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 67. Gilead Sciences Recent Development
Table 68. Roche Company Details
Table 69. Roche Business Overview
Table 70. Roche Cancer Immunotherapy Drugs Product
Table 71. Roche Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 72. Roche Recent Development
Table 73. Bristol-Myers Squibb Company Details
Table 74. Bristol-Myers Squibb Business Overview
Table 75. Bristol-Myers Squibb Cancer Immunotherapy Drugs Product
Table 76. Bristol-Myers Squibb Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 77. Bristol-Myers Squibb Recent Development
Table 78. Amgen Company Details
Table 79. Amgen Business Overview
Table 80. Amgen Cancer Immunotherapy Drugs Product
Table 81. Amgen Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 82. Amgen Recent Development
Table 83. AstraZeneca Company Details
Table 84. AstraZeneca Business Overview
Table 85. AstraZeneca Cancer Immunotherapy Drugs Product
Table 86. AstraZeneca Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 87. AstraZeneca Recent Development
Table 88. Merck & Co Company Details
Table 89. Merck & Co Business Overview
Table 90. Merck & Co Cancer Immunotherapy Drugs Product
Table 91. Merck & Co Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 92. Merck & Co Recent Development
Table 93. Takeda Company Details
Table 94. Takeda Business Overview
Table 95. Takeda Cancer Immunotherapy Drugs Product
Table 96. Takeda Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 97. Takeda Recent Development
Table 98. Merck KGaA Company Details
Table 99. Merck KGaA Business Overview
Table 100. Merck KGaA Cancer Immunotherapy Drugs Product
Table 101. Merck KGaA Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 102. Merck KGaA Recent Development
Table 103. Seagen Company Details
Table 104. Seagen Business Overview
Table 105. Seagen Cancer Immunotherapy Drugs Product
Table 106. Seagen Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 107. Seagen Recent Development
Table 108. Eli Lilly Company Details
Table 109. Eli Lilly Business Overview
Table 110. Eli Lilly Cancer Immunotherapy Drugs Product
Table 111. Eli Lilly Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 112. Eli Lilly Recent Development
Table 113. Ono Pharmaceutical Company Details
Table 114. Ono Pharmaceutical Business Overview
Table 115. Ono Pharmaceutical Cancer Immunotherapy Drugs Product
Table 116. Ono Pharmaceutical Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 117. Ono Pharmaceutical Recent Development
Table 118. Pfizer Company Details
Table 119. Pfizer Business Overview
Table 120. Pfizer Cancer Immunotherapy Drugs Product
Table 121. Pfizer Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 122. Pfizer Recent Development
Table 123. GSK Company Details
Table 124. GSK Business Overview
Table 125. GSK Cancer Immunotherapy Drugs Product
Table 126. GSK Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 127. GSK Recent Development
Table 128. Exelixis Company Details
Table 129. Exelixis Business Overview
Table 130. Exelixis Cancer Immunotherapy Drugs Product
Table 131. Exelixis Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 132. Exelixis Recent Development
Table 133. Regeneron Company Details
Table 134. Regeneron Business Overview
Table 135. Regeneron Cancer Immunotherapy Drugs Product
Table 136. Regeneron Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 137. Regeneron Recent Development
Table 138. Innovent Company Details
Table 139. Innovent Business Overview
Table 140. Innovent Cancer Immunotherapy Drugs Product
Table 141. Innovent Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 142. Innovent Recent Development
Table 143. Hengrui Medicine Company Details
Table 144. Hengrui Medicine Business Overview
Table 145. Hengrui Medicine Cancer Immunotherapy Drugs Product
Table 146. Hengrui Medicine Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)
Table 147. Hengrui Medicine Recent Development
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 151. Authors List of This Report
List of Figures
Figure 1. Cancer Immunotherapy Drugs Picture
Figure 2. Global Cancer Immunotherapy Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Cancer Immunotherapy Drugs Market Share by Type: 2023 VS 2030
Figure 4. Immune Checkpoint Inhibitors Features
Figure 5. Cytokine-Based Immunotherapy Features
Figure 6. CAR-T Cell Therapy Features
Figure 7. Other Features
Figure 8. Global Cancer Immunotherapy Drugs Market Size by Application (2024-2030) & (US$ Million)
Figure 9. Global Cancer Immunotherapy Drugs Market Share by Application: 2023 VS 2030
Figure 10. Lung Cancer Case Studies
Figure 11. Breast Cancer Case Studies
Figure 12. Prostate Cancer Case Studies
Figure 13. Blood-related Cancer Case Studies
Figure 14. Other Case Studies
Figure 15. Cancer Immunotherapy Drugs Report Years Considered
Figure 16. Global Cancer Immunotherapy Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 17. Global Cancer Immunotherapy Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Cancer Immunotherapy Drugs Market Share by Region: 2023 VS 2030
Figure 19. Global Cancer Immunotherapy Drugs Market Share by Players in 2023
Figure 20. Global Top Cancer Immunotherapy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Immunotherapy Drugs as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by Cancer Immunotherapy Drugs Revenue in 2023
Figure 22. North America Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America Cancer Immunotherapy Drugs Market Share by Country (2019-2030)
Figure 24. United States Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Cancer Immunotherapy Drugs Market Share by Country (2019-2030)
Figure 28. Germany Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Cancer Immunotherapy Drugs Market Share by Region (2019-2030)
Figure 36. China Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Japan Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. South Korea Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. India Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Australia Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Cancer Immunotherapy Drugs Market Share by Country (2019-2030)
Figure 44. Mexico Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Brazil Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Cancer Immunotherapy Drugs Market Share by Country (2019-2030)
Figure 48. Turkey Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. UAE Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. AbbVie Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 52. Johnson & Johnson Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 53. Novartis Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 54. Gilead Sciences Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 55. Roche Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 56. Bristol-Myers Squibb Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 57. Amgen Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 58. AstraZeneca Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 59. Merck & Co Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 60. Takeda Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 61. Merck KGaA Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 62. Seagen Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 63. Eli Lilly Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 64. Ono Pharmaceutical Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 65. Pfizer Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 66. GSK Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 67. Exelixis Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 68. Regeneron Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 69. Innovent Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 70. Hengrui Medicine Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
